Sökning: onr:"swepub:oai:DiVA.org:uu-311936" > Maintenance versus ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04951naa a2200973 4500 | |
001 | oai:DiVA.org:uu-311936 | |
003 | SwePub | |
008 | 170103s2017 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:135082530 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3119362 URI |
024 | 7 | a https://doi.org/10.1016/j.bbmt.2016.11.0112 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1350825302 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Cornell, Robert F4 aut |
245 | 1 0 | a Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma |
264 | 1 | b Elsevier BV,c 2017 |
338 | a print2 rdacarrier | |
520 | a Bortezomib (V), lenalidomide (R), cyclophosphamide (C), and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens before autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM) in the United States. In this study we evaluated 693 patients receiving "upfront" AHCT after initial induction therapy with modern doublet or triplet regimens using data reported to the Center for International Blood and Marrow Transplant Research from 2008 to 2013. Analysis was limited to those receiving a single AHCT after 1 line of induction therapy within 12 months from treatment initiation for MM. In multivariate analysis, progression-free survival (PFS) and overall survival were similar irrespective of induction regimen. However, high-risk cytogenetics and nonreceipt of post-transplant maintenance/consolidation therapy were associated with higher risk of relapse. Patients receiving post-transplant therapy had significantly improved 3-year PFS versus no post-transplant therapy (55% versus 39%, P = .0001). This benefit was most evident in patients not achieving at least a complete response post-AHCT (P = .005). In patients receiving upfront AHCT, the choice of induction regimen (doublet or triplet therapies) appears to be of lower impact than use of post-transplant therapy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
653 | a Myeloma | |
653 | a Transplantation | |
653 | a Survival | |
653 | a Relapse | |
653 | a Chemotherapy | |
653 | a Maintenance | |
700 | 1 | a D'Souza, Anita4 aut |
700 | 1 | a Kassim, Adetola A4 aut |
700 | 1 | a Costa, Luciano J4 aut |
700 | 1 | a Innis-Shelton, Racquel D4 aut |
700 | 1 | a Zhang, Mei-Jie4 aut |
700 | 1 | a Huang, Jiaxing4 aut |
700 | 1 | a Abidi, Muneer4 aut |
700 | 1 | a Aiello, Jack4 aut |
700 | 1 | a Akpek, Gorgun4 aut |
700 | 1 | a Bashey, Asad4 aut |
700 | 1 | a Bashir, Qaiser4 aut |
700 | 1 | a Cerny, Jan4 aut |
700 | 1 | a Comenzo, Raymond4 aut |
700 | 1 | a Diaz, Miguel Angel4 aut |
700 | 1 | a Freytes, César4 aut |
700 | 1 | a Gale, Robert Peter4 aut |
700 | 1 | a Ganguly, Siddhartha4 aut |
700 | 1 | a Hamadani, Mehdi4 aut |
700 | 1 | a Hashmi, Shahrukh4 aut |
700 | 1 | a Holmberg, Leona4 aut |
700 | 1 | a Hossain, Nasheed4 aut |
700 | 1 | a Kamble, Rammurti T4 aut |
700 | 1 | a Kharfan-Dabaja, Mohamed4 aut |
700 | 1 | a Kindwall-Keller, Tamila4 aut |
700 | 1 | a Kyle, Robert4 aut |
700 | 1 | a Kumar, Shaji4 aut |
700 | 1 | a Lazarus, Hillard4 aut |
700 | 1 | a Lee, Cindy4 aut |
700 | 1 | a Maiolino, Angelo4 aut |
700 | 1 | a Marks, David I4 aut |
700 | 1 | a Meehan, Kenneth4 aut |
700 | 1 | a Mikhael, Joe4 aut |
700 | 1 | a Nath, Rajneesh4 aut |
700 | 1 | a Nishihori, Taiga4 aut |
700 | 1 | a Olsson, Richard F.u Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD)4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Ramanathan, Muthalagu4 aut |
700 | 1 | a Saad, Ayman4 aut |
700 | 1 | a Seo, Sachiko4 aut |
700 | 1 | a Usmani, Saad4 aut |
700 | 1 | a Vesole, David4 aut |
700 | 1 | a Vij, Ravi4 aut |
700 | 1 | a Vogl, Dan4 aut |
700 | 1 | a Wirk, Baldeep M4 aut |
700 | 1 | a Yared, Jean4 aut |
700 | 1 | a Krishnan, Amrita4 aut |
700 | 1 | a Mark, Tomer4 aut |
700 | 1 | a Nieto, Yago4 aut |
700 | 1 | a Hari, Parameswaran4 aut |
710 | 2 | a Uppsala universitetb Centrum för klinisk forskning i Sörmland (CKFD)4 org |
773 | 0 | t Biology of blood and marrow transplantationd : Elsevier BVg 23:2, s. 269-277q 23:2<269-277x 1083-8791x 1523-6536 |
856 | 4 | u http://www.bbmt.org/article/S108387911630489X/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-311936 |
856 | 4 8 | u https://doi.org/10.1016/j.bbmt.2016.11.011 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:135082530 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy